GlassScriptPhysician profile
Vy T Le
NPI 1134674443
$9,013.19
in general payments reported to CMS, 2019-2025
37 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $562 · 2021: $1,623 · 2022: $1,126 · 2023: $787 · 2024: $1,896 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,623.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,319.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $930.89 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.66 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $499.93 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $469.63 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $418.20 | 2020-2025 | |
| Amgen INC. | $396.77 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $300.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $224.35 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.77 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $184.80 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $172.11 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $152.30 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $146.58 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.